Novo Nordisk | NVO - Cash And Equivalent


Novo Nordisk reported DKK38.94B in Cash and Equivalent for its fiscal quarter ending in March of 2025.





Cash And Equivalent Change Date
ANI Pharmaceuticals USD 311.18M 25.59M Mar/2026
Aurora Cannabis CAD 56.36M 39.33M Dec/2025
Bausch Health Companies USD 1.31B 1000K Dec/2025
Bristol-Myers Squibb USD 9.57B 635M Mar/2026
Canopy Growth CAD 371.32M 73.26M Dec/2025
Corcept Therapeutics USD 108.74M 11.76M Mar/2026
Drreddys Laboratories INR 18.66B 9.65B Dec/2025
Eli Lilly USD 5.28B 1.99B Mar/2026
GlaxoSmithKline GBP 3.44B 292M Mar/2026
Merck USD 5.33B 9.24B Mar/2026
Nektar Therapeutics USD 15.12M 25.92M Dec/2025
Novartis USD 6.88B 4.56B Mar/2026
Novo Nordisk DKK 38.94B 24.15B Mar/2025
Novo Nordisk A/S DKK 18.44B 5.78B Jun/2025
Pacira USD 144.31M 14.24M Mar/2026
Perrigo USD 531.6M 99.5M Dec/2025
Phibro Animal Health USD 54.93M 557K Mar/2026
Prestige Brands USD 63.87M 1.5M Mar/2026
Sanofi EUR 7.66B 1.25B Dec/2025
Supernus Pharmaceuticals USD 184.87M 56.42M Mar/2026
Zoetis USD 1.94B 369M Mar/2026